Top HIV/AIDS Stories of 2007
A perspective on the years most important stories in HIV medicine
Top HIV/AIDS Stories of 2006
HIV/AIDS
Letter to Readers
Free
The ACC editors offer their perspective on the years most important stories in HIV medicine.
By Paul E. Sax, MD
December 29, 2006
New CDC HIV Testing Guidelines for Adults and Adolescents
Routine HIV screening should now be offered at all points of care to all individuals aged 13 to 64, regardless of their potential risk for infection.
By Judith Feinberg, MD
December 29, 2006
One Pill, Once Daily = Triple Therapy for HIV
A single tablet contains efavirenz, tenofovir, and FTC, one of the most effective triple-drug regimens available for treatment-naive patients.
By Paul E. Sax, MD
December 29, 2006
Resistance Testing: A New Emphasis on Detecting Transmitted Resistance
All HIV-infected patients should undergo genotype testing prior to initiation of antiretroviral therapy.
By Charles B. Hicks, MD
December 29, 2006
Standard Triple-Drug Regimens Remain the Best for Initial Therapy
Efavirenz-based regimens appear to be particularly effective.
By Abigail Zuger, MD
December 29, 2006
Expanded HIV Treatment in Resource-Poor Countries
Initial concerns that antiretroviral therapy would be less effective in resource-poor settings or that patients there would be less adherent appear to be unfounded.
By Carlos del Rio, MD
December 29, 2006
Promising New Options for Treatment-Experienced Patients
Even triple-classexperienced patients can achieve virologic suppression with some of the new agents now available.
By Helmut Albrecht, MD
December 29, 2006
Discouraging News on Structured Treatment Interruption
Structured treatment interruptions that allow CD4 counts to drop below 350 cells/mm3 are unsafe and should not be recommended.
By Keith Henry, MD
December 29, 2006
XDR TB: A Growing Public Health Concern
Global increases in multidrug-resistant and extensively drug-resistant TB are threatening both TB and HIV treatment programs worldwide and raise concerns about a future epidemic of virtually untreatable TB.
By Salim S. Abdool Karim, MD, PhD
December 29, 2006